William Blair analyst Tim Lugo downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Outperform to Market Perform.
Wolfe Research Upgrades World Wrestling Enter to Outperform, Announces $98 Price Target
Wolfe Research analyst Peter Supino upgrades World Wrestling Enter (NYSE:WWE) from Peer Perform to Outperform and announces $98 price target.